New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread
5 January 2022
- A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms.
- The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.
- This early cancer detection test uses NMR metabolomics technology to analyse a simple blood sample.
A University of Oxford study published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, outlines a new type of blood test that can be used to detect a range of cancers and whether these cancers have spread (metastasised) in the body. The study analysed samples from 300 patients with non-specific but concerning symptoms of cancer, such as fatigue and weight loss, who were recruited through the Oxfordshire Suspected CANcer (SCAN) pathway.
The researchers assessed whether the test could distinguish patients with a range of solid tumours from those without cancer. Their results show that cancer was correctly detected in 19 out of every 20 patients with cancer using this test. In those with cancer, metastatic disease was identified with an overall accuracy of 94%. These results make this the first technology to be able to determine the metastatic status of a cancer from a simple blood test, without prior knowledge of the primary cancer type.
This test shows promise to help clinicians detect cancer and assess cancer stage in the future. Unlike many blood-based tests for cancer, which detect genetic material from tumours, this test uses a technique called NMR metabolomics, which uses high magnetic fields and radio waves to profile levels of natural chemicals (metabolites) in the blood. Healthy individuals, people with localised cancer, and people with metastatic cancer each have different profiles of blood metabolites, which can be detected and then analysed by the researchers’ algorithms to distinguish between these states.
Dr James Larkin, researcher on the study from the University of Oxford, says: “Cancer cells have unique metabolomic fingerprints due to their different metabolic processes. We are only now starting to understand how metabolites produced by tumours can be used as biomarkers to accurately detect cancer. We have already demonstrated that this technology can successfully identify if patients with multiple sclerosis are progressing to the later stages of disease, even before trained clinicians could tell. It is very exciting that the same technology is now showing promise in other diseases, like cancer.”
Cancers detected earlier are more likely to be treated successfully. This rapid and inexpensive test could help to overcome many barriers to the early detection of cancer, especially in patients that present with non-specific symptoms, which do not direct investigations towards a specific organ. NHS Rapid Diagnostic Centres, similar to Oxfordshire’s SCAN pathway, are currently being set up across the NHS to support faster and earlier cancer diagnosis in all patients with symptoms that could indicate cancer.
This new test is not specific to a single cancer type and has shown promise in this traditionally challenging clinical context, including the potential to detect some cancers in the community before conventional imaging is performed.
Dr Fay Probert, lead researcher of the study from the University of Oxford, says: “This work describes a new way of identifying cancer. The goal is to produce a test for cancer that any GP can request. We envisage that metabolomic analysis of the blood will allow accurate, timely and costeffective triaging of patients with suspected cancer, and could allow better prioritisation of patients based on the additional early information this test provides on their disease.”
Future studies with larger patient cohorts will further evaluate this technique for the earlier detection of new cancers and potential clinical applications.
Notes to editors:
Contact: Megan Harvey, firstname.lastname@example.org, +44 7485 187 131 Interviews: Dr James Larkin is available for interview on request.
This research was published in Clinical Cancer Research and can be read here: http://clincancerres.aacrjournals.org/content/early/2021/12/16/1078-0432.CCR-21-2855
This research was funded by Cancer Research UK, the Oxford Centre for Early Cancer Detection (OxCODE), the EPSRC Cancer Imaging Centre in Oxford, the National Institute for Health Research (NIHR) Community Healthcare Medtech and In-Vitro Diagnostics Co-operative, and the OxfordWellcome Institutional Strategic Support Fund.
University of Oxford Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions. Oxford University’s cancer research is managed through Oxford Cancer: a city-wide network and partnership between Oxford University and Oxford University Hospitals NHS Foundation Trust. With over 900 cancer research scientists spread across the city and beyond, Oxford is ideally placed to enable and combine the best research and clinical resources in order to innovate cancer treatment and care world-wide.
Learn more at www.cancer.ox.ac.uk